Zejula

Active Ingredient(s): Niraparib
FDA Approved: * March 27, 2017
Pharm Company: * TESARO INC
Category: Cancer

Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2][3][4] It is taken by mouth.[2][3] It is a PARP inhibitor. The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Zejula 100 mg Oral Tablet, Film Coated
NDC: 0173-0909
Labeler:
Glaxosmithkline LLC
Zejula 200 mg Oral Tablet, Film Coated
NDC: 0173-0912
Labeler:
Glaxosmithkline LLC
Zejula 300 mg Oral Tablet, Film Coated
NDC: 0173-0915
Labeler:
Glaxosmithkline LLC
Zejula 100 mg Oral Capsule
NDC: 69656-103
Labeler:
Tesaro, Inc.

Popular Topics

Zejula (Niraparib) Discussion Forum

This is my 5th week on Zejula 200mg daily. As suggested by the pharmacy nurse I take it at night to help with possible s...

4 REPLIES